Abstracts Archive - Page 847 of 2425 - ACR Meeting Abstracts

Abstract Number: 1329 • 2019 ACR/ARP Annual Meeting
Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Kevin Winthrop¹, Mark Genovese ², Bernard Combe ³, Yoshiya Tanaka ⁴, Alan Kivitz ⁵, Franziska Matzkies ⁶, Beatrix Bartok ⁶, Lei Ye ⁶, Ying Guo ⁶, Chantal Tasset ⁷, John Sundy ⁶, Edward Keystone ⁸, Rene Westhovens ⁹, William F.C. Rigby ¹⁰ and Gerd Burmester ¹¹, ¹Oregon Health and Science University, Portland, OR, ²Stanford University, Stanford, CA, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, ⁸Mount Sinai Hospital and University of Toronto, Toronto, Canada, ⁹University Hospitals, Leuven, Belgium, ¹⁰Dartmouth College, Lebanon, NH, ¹¹Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) that is under development for the treatment of RA and other…
Abstract Number: 1330 • 2019 ACR/ARP Annual Meeting
No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years
Anja Strangfeld¹, Klaus Krüger ², Bernhard Manger ³, Christian Kneitz ⁴, Angela Zink ⁵ and Martin Schaefer ⁶, ¹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²Rheumatologist, München, Germany, ³Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁴Rheumatologist, Schwerin, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, ⁶German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Due to demographic changes an increasing number of persons reach an age above 70 years. Therefore, the adequate therapy of elderly patients with rheumatoid…
Abstract Number: 1331 • 2019 ACR/ARP Annual Meeting
No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab
Anja Strangfeld¹, Yvette Meissner ², Martin Schaefer ³, Lisa Baganz ², Matthias Schneider ⁴, Elke Wilden ⁵, Silke Zinke ⁶ and Angela Zink ⁷, ¹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁵Rheumatologist, Cologne, Germany, ⁶Rheumatologist, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University medicine, Berlin, Germany
Background/Purpose: Spontaneous reports of nine facial paralyses and five facial pareses made by healthcare professionals from Europe have recently prompted EMA’s Pharmacovigilance Risk Assessment Committee…
Abstract Number: 1332 • 2019 ACR/ARP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Sergio Schwartzman¹, Aaron Broadwell ², Alan Kivitz ³, Shawn Black ⁴, Stephen Xu ⁵ and Shelly Kafka ⁶, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, RI, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 1333 • 2019 ACR/ARP Annual Meeting
The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea
Eun Hye Park¹, Anna Shin ², Yaa-Hui Dong ³, You-Jung Ha ¹, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ⁶ and Eun Ha Kang ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan (Republic of China), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ⁶Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of osteoporosis and osteoporotic fracture, but little is known about comparative risk of osteoporotic fractures between…
Abstract Number: 1334 • 2019 ACR/ARP Annual Meeting
Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Dalifer Freites Nuñez¹, Leticia León ², Marta Redondo ³, Cristina Vadillo Font ⁴, Pia Lois ⁵, Arkaitz Mucientes Ruiz ⁴, Luis Rodríguez-Rodríguez ⁶, Benjamín Fernández Gutiérrez ⁷, Juan Angel Jover Jover ⁴ and lydia Abasolo Alcazar ⁴, ¹Hospital Clínico San Carlos, MADRID, Spain, ²Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, ³Universidad Camilo José Ceja, Madrid, Madrid, Spain, ⁴HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Fundación para la Investigación Biomedica, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid
Background/Purpose: Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. The experience of fatigue…
Abstract Number: 1335 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study
Sarah Homann¹, Carlos Grijalva ¹, S. Bobo Tanner ¹ and James Morrow ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a much greater risk of sustaining a hip fracture than those without RA. Hip fractures cause significant morbidity…
Abstract Number: 1336 • 2019 ACR/ARP Annual Meeting
Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis
Daniel Aletaha¹, Ruta Sawant ², Patrick Zueger ³, Erin Cook ⁴, Fan Mu ⁴, Vishvas Garg ² and Keith A. Betts ⁴, ¹Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Biologic (b) and targeted synthetic (ts) DMARDs have demonstrated efficacy for the treatment of rheumatoid arthritis (RA) in clinical trials; however, real-world evidence on…
Abstract Number: 1337 • 2019 ACR/ARP Annual Meeting
Fatigue Levels Are Not Associated with Inflammatory Activity, but with Subjective Outcomes: Results from a Longitudinal Study of Patients with Rheumatoid Arthritis Initiating bDMARD Therapy
Hilde Hammer¹, Brigitte Michelsen ², Joe Sexton ³, Sella Provan ¹, Till Uhlig ⁴ and Tore Kvien ⁴, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway
Background/Purpose: Fatigue is a sensation of weakness and lack of energy which is common in patients with rheumatoid arthritis (RA), contributing to reduced quality of…
Abstract Number: 1338 • 2019 ACR/ARP Annual Meeting
Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start
Mojca Frank-Bertoncelj¹, Oliver Distler ², Tim Killeen ³, Kenneth Kwok ⁴, Lisy Wang ⁵, Caroline Ospelt ¹ and Adrian Ciurea ¹, ¹University Hospital Zürich, Zürich, Switzerland, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Pfizer AG, Zürich, Switzerland, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses…
Abstract Number: 1339 • 2019 ACR/ARP Annual Meeting
Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
Elizaveta Efuni ¹, Samuel Cytryn ², Patrick Boland ² and Sabina Sandigursky³, ¹New York University School of Medicine, New York, NY, ²NYU Langone Health, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape in oncology leading to cures in some cancer types. However, patients with pre-existing autoimmune diseases…
Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk ², Orit Schieir ³, Marie-France Valois ⁴, Susan J. Bartlett ⁵, Louis Bessette ⁶, Gilles Boire ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Carter Thorne ¹¹, Diane Tin ¹² and Glen Hazlewood ¹, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York City, NY, ³University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ⁴McGill University, Montreal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷Sherbrooke University, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Canada
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
Abstract Number: 1341 • 2019 ACR/ARP Annual Meeting
Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis
Shmuel Tiosano ¹, Yarden Yavne ¹, Abdulla Watad ², Pnina Langevitz ³, Merav Lidar ⁴, Joy Feld ⁵, Moshe Tishler ⁶, Suhail Aamar ⁷, Ori Elkayam ⁸, Alexandra Balbir-Gurman ⁹, Yair Molad ¹⁰, Sharon Ehrlich ¹¹, Daniela Amital ¹² and Howard AMITAL¹, ¹Department of Medicine B, Ramat-Gan, Israel, ²Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, ³Rhematology Unit, Ramat-Gan, Israel, ⁴Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶5Internal Department B, Assaf Harofeh Medical Center, Zrifin, Israel, Zrifin, Israel, ⁷Rheumatology Unit, Hadassah Mount Scopus Medical Center, Jeursalem, Israel, Jerusalem, Israel, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁹Rambam Medical Center, Haifa, Israel, ¹⁰Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, HaMerkaz, Israel, ¹¹Roche Pharmaceuticals (Israel) Ltd., Hod HaSharon, Israel., Hod-Hashaon, Israel, ¹²Ness Ziona Beer-Yaacov Mental Health Center,, Beer-Yaakov, Israel
Background/Purpose: Mood disorders, such as anxiety and depression are extremely prevalent amongst patients with rheumatoid arthritis (RA). In this study we sought to assess the…
Abstract Number: 1342 • 2019 ACR/ARP Annual Meeting
Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis
Joseph Patrick Michele Blair¹, Cecilie Bager ², Man Hung Eric Tang ², Morten Karsdal ³, Anne Bay-Jensen ⁴ and Søren Brunak ⁵, ¹Univeristy of Copenahgen, Copenhagen, Denmark, ²Nordic Bioscience ProScion, Copenhagen, Denmark, ³Nordic Bioscience, Copenhagen, Denmark, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease with a fluctuating course of disease activity and progression. Although treatments have improved substantially in recent…
Abstract Number: 1343 • 2019 ACR/ARP Annual Meeting
Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)
Jasvinder Singh¹, Haley Tornberg ² and Susan Goodman ³, ¹University of Alabama Medical Center, Birmingham, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Little is known about the patient perspective related to DMARD choice in RA. Our objective was to assess how patients decide whether to add…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].